Mr. Ian Atacan reports

PHARMACIELO ANNOUNCES THE ISSUANCE OF INTEREST SHARES

As approved by the TSX Venture Exchange, Pharmacielo Ltd. is issuing 12,153,937 common shares of Pharmacielo at an effective price of eight cents per interest share in satisfaction of an aggregate of $972,317.12 of semi-annual interest payable to holders of the company's 11 per cent secured debentures.

The effective price of the interest shares was determined by dividing the cash interest otherwise payable by the number of shares issuable under each debenture in accordance with the terms of the debentures and TSX-V Policy 4.3, Section 3.3. The interest shares are subject to the balance, if any, of the four-month statutory hold period.

The issuance of interest shares to L5 Capital Inc., Marc Lustig, William Petron and Ian Atacan constitutes a related-party transaction within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). The company is relying on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101 as the fair market value of the transaction does not exceed 25 per cent of the company's market capitalization.

Annual general and special meeting

The company's next annual general meeting will be held on April 2, 2026, at 11 a.m. Eastern Time at 82 Richmond St. East, Toronto, Ont., M5C 1P1. Shareholders will be asked to elect directors, appoint an auditor and consider other customary business. Shareholders may also participate in the meeting on-line or by dialling in at the below dial-in number approximately five to 10 minutes prior to the scheduled start time.

Date and time:  Thursday, April 2, 2026, at 11 a.m. Toronto time

Dial-in numbers:  1-689-278-1000, 96949238343 followed by the number sign, or 1-719-359-4580, 96949238343 followed by the number sign, from Canada or the U.S.

Meeting ID:  969 4923 8343

Passcode:  527692 followed by the number sign

About Pharmacielo Ltd.

Pharmacielo is a global company, headquartered in Canada, with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medicinal, and commercial dried cannabis flower and cannabis products to large channel distributors. Pharmacielo's principal (and wholly owned) subsidiary is Pharmacielo Colombia Holdings SAS, headquartered at its cultivation and processing centre located in Rionegro, Colombia.

We seek Safe Harbor.